Liraglutide for the treatment of type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials (Q35411439)

8 August 2017

0 references

Liraglutide for the treatment of type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials (English)

1 reference

8 August 2017

1 reference

1 reference

Qiang Du

1

1 reference

8 August 2017

Yan-Jun Wang

2

1 reference

8 August 2017

Sheng Yang

3

1 reference

8 August 2017

Yue-Yang Zhao

4

1 reference

8 August 2017

Ping Han

5

1 reference

8 August 2017

language of work or name

English

0 references

publication date

12 November 2014

1 reference

8 August 2017

1 reference

8 August 2017

31

1 reference

8 August 2017

11

1 reference

8 August 2017

1182-1195

1 reference

https://scigraph.springernature.com/pub.10.1007/s12325-014-0164-2

8 August 2017

0 references

cites work

Global estimates of diabetes prevalence for 2013 and projections for 2035.

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0164-2

Diabetic retinopathy: current concepts and emerging therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0164-2

Diabetic nephropathy - complications and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0164-2

Meta-analysis of methylcobalamin alone and in combination with lipoic acid in patients with diabetic peripheral neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0164-2

Blood pressure and diabetes: a fatal attraction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0164-2

Update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0164-2

The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0164-2

The economic impact of diabetes through lost labour force participation on individuals and government: evidence from a microsimulation model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0164-2

The high-cost, type 2 diabetes mellitus patient: an analysis of managed care administrative data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0164-2

Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0164-2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0164-2

Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0164-2

Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0164-2

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0164-2

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0164-2

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0164-2

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0164-2

Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0164-2

Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0164-2

The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0164-2

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0164-2

Evaluation of the endorsement of the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement on the quality of published systematic review and meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0164-2

Identification of direct and indirect social network effects in the pathophysiology of insulin resistance in obese human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0164-2

Insulin-associated weight gain in diabetes--causes, effects and coping strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0164-2

Role of insulin resistance in endothelial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0164-2

Vildagliptin more effectively achieves a composite endpoint of HbA₁c < 7.0% without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0164-2

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0164-2

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0164-2

Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0164-2

Liraglutide protects pancreatic beta cells during an early intervention in Gato-Kakizaki rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0164-2

Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0164-2

Liraglutide therapy in obese people with type 2 diabetes - experience of a weight management centre.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0164-2

Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0164-2

Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0164-2

10.1007/S12325-014-0164-2

21 January 2018

Identifiers

DOI

1 reference

8 August 2017

1 reference